SPITALUL UNIVERSITAR C . F . 2
Bucharest / ROMANIA

RENALOF

IN THE TREATMENT OF

RENAL LITHIASIS AND MICROLITHIASIS

Dr. Med. Constantin Nitoiu
Dr. Bucur Ovidiu-Mihai

Urology and Urological Surgery Departments
UNIVERSITY HOSPITAL C . F . 2
Bucharest / ROMANIA

January – June 2005

CATALYSIS, S.L.
The Treatment of Renal Lithiasis and Microlithiasis with the Preparation RENALOF

stage IV clinical study aimed to determine the tolerance, compliance and efficacy of RENALOF in patients with renal lithiasis and microlithiasis

Number of Patients: 135

<table>
<thead>
<tr>
<th></th>
<th>Treated Group</th>
<th>Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>100</td>
<td>35</td>
</tr>
<tr>
<td>Average age</td>
<td>47.5 years</td>
<td>48.25 years</td>
</tr>
</tbody>
</table>

Duration of the Treatment: 30 days

Therapy: monotherapy with RENALOF

Dose: 3 capsules of RENALOF per day

The patients were subjected to clinical and imagistic observation (ECHO ± radiological) at the beginning and at the end of the study.

**CONCLUSIONS**

- Excellent tolerance of the treatment with the absence of adverse effects and the total compliance with the treatment.

- Improvement of the general condition of the patients with a high efficacy in the reduction of lumbar pain.

- **100% efficacy in the elimination of ureteral calculi.**

- **High efficacy in the short treatment of voluminous renal microlithiasis and lithiasis,** suggesting a longer treatment (3 – 6 months) for the solution of the pathology.

- Use of RENALOF as a prophylactic treatment in patients with a predisposition to oxalic lithogenesis.